Galapagos (GLPG) Q1 2026 earnings summary

Executive summary

• Completed a major transformation with new leadership, board changes, and rebranding to Lakefront Biotherapeutics, effective May 8, 2026.

• Entered a binding agreement with Gilead to jointly acquire Ouro Medicines, adding BCMA/CD3 T-cell engager gamgertamig and preclinical assets to the pipeline.

• Gamgertamig has shown rapid, durable responses and minimal cytokine release syndrome in over 60 patients across five autoimmune indications, with Fast Track and Orphan Drug Designation in the U.S.; registrational studies expected in 2027.

• Wind-down of cell therapy activities is on track, with completion expected by end of Q3 2026.

• Board changes include Gino Santini appointed as Chair, replacing Jérôme Contamine.

Financial highlights

• Q1 2026 net revenues were €6.5M, down 91% year-over-year, mainly due to the absence of prior year’s one-time revenue recognition.

• Operating loss improved to €63.7M from €158.7M in Q1 2025, reflecting lower R&D and restructuring costs.

• Net profit of €14.5M in Q1 2026, compared to a net loss of €153.4M in Q1 2025, driven by fair value and currency gains.

• Cash and financial investments totaled €2,982.2M at March 31, 2026.

• Net financial income rose to €77.7M, driven by fair value gains and currency exchange effects.

Outlook and guidance

• Year-end 2026 cash and investments projected at €1.975B–€2.05B, reflecting Ouro transaction and cell therapy wind-down.

• Estimated 2026 cash spend related to Ouro: €775M–€790M, including upfront, transaction, and operating costs.

• One-time cash restructuring costs for cell therapy wind-down expected at €125M–€175M in 2026.

• Up to $500M available for business development outside Gilead partnership, including up to $150M for share repurchases.

• Majority of current cash (~€3B) to remain available for strategic transactions post-Ouro deal.